Somatostatin Analogs Market Players:
- Novartis AG
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Sun Pharmaceutical Industries Ltd
- Midatech Pharma PLC
- Ipsen Pharma, Chiasma Inc.
- Peptron, Inc
- CRINETICS PHARMACEUTICALS
- Dauntless Pharmaceuticals
- Camurus AB
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2026, the industry size of somatostatin analogs is assessed at USD 8.09 billion.
The global somatostatin analogs market size was around USD 8.09 billion in 2026 and is likely to expand at a CAGR of more than 7.3%, surpassing USD 16.37 billion revenue by 2036.
North America is anticipated to hold a 49% share by 2036 in the somatostatin analogs market, driven by the presence of major regional players such as Pfizer Inc. and Novartis AG.
Key players in the market include Takeda Pharmaceutical Company Limited, ActoBio Therapeutics, Inc., Precigen, Inc., Calypso Biotech BV, ImmunogenX, Inc., Alvine Pharmaceuticals, Dr. Falk Pharma GmbH, ImmusanT, Inc., Zedira GmbH, FunZyme BioTechnologies S.A., Amyra Biotech AG.
